Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2107)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (105)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4652)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Larotrectinib in non-CNS TRK fusion cancer patients: Outcomes by prior therapy and performance status
    Meeting Abstract

    Drilon, A.; Shen, L.; van Tilburg, C. M.; Tan, D. S. W.; Kummar, S.; Lin, J. J.; Doz, F.; McDermott, R.; Albert, C. M.; Berlin, J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase (TRK) fusion cancer
    Meeting Abstract

    Brose, M. S.; Shen, L.; Tan, D. S. W.; Kummar, S.; Lin, J. J.; McDermott, R.; Berlin, J.; Tahara, M.; Lassen, U. N.; Leyvraz, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Incidence of fractures in TRK fusion cancer patients treated with larotrectinib
    Meeting Abstract

    Laetsch, T. W.; van Tilburg, C. M.; Kummar, S.; Dowlati, A.; Guiver, K.; Fellous, M.; Brega, N.; De La Cuesta, E.; Shurshalina, A.; Drilon, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Pembrolizumab (pembro) for previously treated, microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Final analysis of KEYNOTE-164
    Meeting Abstract

    Le, D. T.; Diaz, L.; Kim, T. W.; Van Cutsem, E.; Geva, R.; Jäger, D.; Hara, H.; Burge, M.; O'Neil, B.; Kavan, P.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • CodeBreaK 101 subprotocol H: Phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC)
    Meeting Abstract

    Fakih, M.; Falchook, G. S.; Hong, D. S.; Yaeger, R. D.; Chan, E.; Mather, O.; Cardona, P.; Dai, T.; Strickler, J.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Genomic characterization and clinical outcomes of patients (pts) with metastatic colorectal cancer (mCRC) with peritoneal metastases (PM) in AACR project GENIE
    Meeting Abstract

    Sanz Garcia, E.; Riely, G. J.; Lepisto, E. M.; LeNoue-Newton, M. L.; Warner, J. L.; Sweeney, S. M.; McCarthy, C. G.; Weiss, J.; Yu, C.; Voon, P. J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Efficacy and safety of entrectinib in patients with locally advanced/ metastatic NTRK fusion-positive (NTRK-fp) solid tumours
    Meeting Abstract

    Bazhenova, L.; Liu, S. V.; Lin, J. J.; Lu, S.; Drilon, A.; Chawla, S. P.; Fakih, M.; Krzakowski, M.; Paz-Ares, L.; Blakely, C.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+ / human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC)
    Meeting Abstract

    Chandarlapaty, S.; Linden, H. M.; Neven, P.; Petrakova, K.; Bardia, A.; Kabos, P.; Braga, S.; Boni, V.; Pelekanou, V.; Ternès, N.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)
    Meeting Abstract

    Saura Manich, C.; Modi, S.; Krop, I.; Park, Y. H.; Kim, S. B.; Tamura, K.; André, F.; Iwata, H.; Ito, Y.; Tsurutani, J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • AMEERA-1: Phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+ / human epidermal growth factor receptor 2-negative (HER2-) PIK3CA-mutated advanced breast cancer
    Meeting Abstract

    Campone, M.; Bardia, A.; Kabos, P.; Chandarlapaty, S.; Neven, P.; Boni, V.; Lord, S.; Cartot-Cotton, S.; Celanovic, M.; Gosselin, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save